# Global regulatory collaboration for the assessment of lenacapavir as a long-acting pre-exposure prophylaxis against HIV infection

**Authors:** Hendy Kristyanto, María Isabel González-Tomé, Viktor Vlcek, Filip Josephson, Patrick Vrijlandt, Nicholas Perombelon

PMC · DOI: 10.3389/fpubh.2026.1760130 · Frontiers in Public Health · 2026-02-16

## Full-text entities

- **Diseases:** HIV infection (MESH:D015658), infection (MESH:D007239)
- **Chemicals:** cabotegravir (MESH:C584914), testosterone (MESH:D013739), progesterone (MESH:D011374), tenofovir diphosphate (MESH:C583447), Lenacapavir (-), tenofovir disoproxil fumarate (MESH:D000068698), estradiol (MESH:D004958)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606], Microsphaeropsis sp. Gt (species) [taxon 1636481]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950762/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950762/full.md

---
Source: https://tomesphere.com/paper/PMC12950762